Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Assets (2016 - 2025)

Arrowhead Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $429.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 3.02% year-over-year to $429.8 million; the TTM value through Dec 2025 reached $1.7 billion, changed 0.1%, while the annual FY2025 figure was $434.7 million, 2.18% down from the prior year.
  • Non-Current Assets reached $429.8 million in Q4 2025 per ARWR's latest filing, down from $434.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $444.3 million in Q3 2024 to a low of $170.0 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $353.2 million, with a median of $337.4 million recorded in 2023.
  • The largest YoY upside for Non-Current Assets was 71.05% in 2021 against a maximum downside of 31.05% in 2021.
  • A 5-year view of Non-Current Assets shows it stood at $300.3 million in 2021, then increased by 5.4% to $316.5 million in 2022, then rose by 22.72% to $388.4 million in 2023, then increased by 14.1% to $443.2 million in 2024, then fell by 3.02% to $429.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Non-Current Assets are $429.8 million (Q4 2025), $434.7 million (Q3 2025), and $433.7 million (Q2 2025).